Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.

Urol Oncol 2016 12 20;34(12):566-576. Epub 2016 Oct 20.

Departments of Oncology and Urology at Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University in Baltimore, Baltimore, MD. Electronic address:

Tremendous advances in our understanding of the tumor immunology and molecular biology of urothelial carcinoma (UC) have led to the recent approval of immunotherapy as a novel option for patients with UC with advanced disease. Despite the promising data of novel immune checkpoint inhibitors, only a small subset of patients with UC achieves durable remissions. Because an optimal antitumor response requires coordination of multiple immune, tumor, and microenvironment effector cells, novel approaches targeting distinct mechanisms of action likely in combination are needed. In addition, discovery of reliable immune biomarkers, understanding of mechanisms of resistance, and novel clinical trial designs are warranted for maximum benefit of UC immunotherapy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2016.09.002DOI Listing
December 2016
3 Reads

Publication Analysis

Top Keywords

novel
5
reliable immune
4
inhibitors small
4
checkpoint inhibitors
4
immune biomarkers
4
small subset
4
subset patients
4
achieves durable
4
patients achieves
4
discovery reliable
4
immune checkpoint
4
addition discovery
4
despite promising
4
targeting distinct
4
mechanisms resistance
4
understanding mechanisms
4
promising data
4
biomarkers understanding
4
novel immune
4
data novel
4

Similar Publications